Categories: EHRNewsPharmaceutical

Clene to Present at the 37TH Annual Roth Conference

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

SALT LAKE CITY, March 06, 2025 (GLOBE NEWSWIRE) — Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will participate in a fireside chat at the 37th Annual Roth Conference and host 1×1 investor meetings.

Date: March 18, 2025
Time of Presentation: 9:20 am PST
Format: Virtual Fireside Chat
1×1 Meetings: Please contact your Roth representative.

A webcast of the presentation will be available on the “Events” section of the Clene website. Alternatively, one can register online to view the webcast here: link.

About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.

Contacts:

Media Contact
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310
  Investor Contact
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
617-283-2856

Staff

Recent Posts

Waystar Appoints Aashima Gupta and Michael Roman to Board of Directors

New directors bring deep expertise in AI innovation, healthcare, and enterprise growth LEHI, Utah and…

4 hours ago

Occupational Health Market to Reach USD 8,453.96 million By 2032, Growing At An 6.50% CAGR – Credence Research

PUNE, India, June 16, 2025 /PRNewswire/ -- The global Occupational Health Market was valued at USD…

4 hours ago

AdventHealth Tampa first in region to perform colorectal surgery using da Vinci SP robot

TAMPA, Fla., June 16, 2025 /PRNewswire/ -- AdventHealth Tampa is now the first hospital in…

4 hours ago

AARP Services Announces New AARP Member Benefits Launching This Summer

WASHINGTON, June 16, 2025 /PRNewswire/ -- Today, it has been announced that AARP members have the…

4 hours ago

C-Path’s New Paper in Nature Reviews Drug Discovery Highlights How to Maximize the Regulatory Impact of Consortium-Based Projects

BRUSSELS and AMSTERDAM, June 16, 2025 /PRNewswire/ -- The Innovative Health Initiative (IHI) and Critical…

4 hours ago

Introducing Archy Intelligence™: Your Newest (AI) Team Members

Archy unveils the future of dental software—where AI works like a teammate, not just a…

4 hours ago